CD8 效应 T 细胞增强 Teclistamab 在 BCMA 暴露与未暴露的多发性骨髓瘤中的缓解
这项真实世界回顾性研究纳入 52 例晚期复发/难治多发性骨髓瘤患者,评估商业化 teclistamab 的疗效与免疫相关因素。总体缓解率为 64%,既往接受过抗 BCMA 治疗者缓解率为 50%。治疗前浆细胞 BCMA 表达水平与缓解无关,而效应 CD8+ T 细胞群与缓解相关、调节性 T 细胞群与未缓解相关。
要点
- teclistamab 治疗 52 例晚期 R/RMM 总体缓解率为 64%。
- 既往接受抗 BCMA 治疗者缓解率为 50%。
- 治疗前浆细胞 BCMA 表达水平与缓解无关。
核心结论
- 在晚期复发/难治多发性骨髓瘤真实世界中,teclistamab 高效,既往抗 BCMA 暴露者仍可缓解。
- 治疗前免疫状态可能参与结局,并可能作为指导患者管理的生物标志物特征。
研究设计与样本
- 真实世界回顾性研究,纳入 52 例接受商业化 teclistamab 的晚期复发/难治多发性骨髓瘤患者,同时采集临床结局与治疗反应的免疫相关指标。
主要发现
- 总体缓解率为 64%。
- 既往接受过抗 BCMA 治疗的患者缓解率为 50%。
- 治疗前浆细胞 BCMA 表达水平与缓解无关。
- 治疗前全面免疫分析显示效应 CD8+ T 细胞群与治疗缓解相关,调节性 T 细胞群与未缓解相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Teclistamab, a B-cell maturation antigen (BCMA)- and CD3-targeting bispecific antibody, is an effective novel treatment for relapsed/refractory multiple myeloma (R/RMM), but efficacy in patients exposed to BCMA-directed therapies and mechanisms of resistance have yet to be fully delineated. We conducted a real-world retrospective study of commercial teclistamab, capturing both clinical outcomes and immune correlates of treatment response in a cohort of patients (n = 52) with advanced R/RMM. Teclistamab was highly effective with an overall response rate (ORR) of 64%, including an ORR of 50% for patients with prior anti-BCMA therapy. Pretreatment plasma cell BCMA expression levels had no bearing on response. However, comprehensive pretreatment immune profiling identified that effector CD8+ T-cell populations were associated with response to therapy and a regulatory T-cell population associated with nonresponse, indicating a contribution of immune status in outcomes with potential utility as a biomarker signature to guide patient management.
引用
- Firestone RS, McAvoy D, Shekarkhand T, et al. CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma. Blood Adv. 2024. PMID: 37878808. doi:10.1182/bloodadvances.2023011225
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。